<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727763</url>
  </required_header>
  <id_info>
    <org_study_id>IMPROVEMENT</org_study_id>
    <nct_id>NCT03727763</nct_id>
  </id_info>
  <brief_title>Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)</brief_title>
  <official_title>Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and&#xD;
      cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>up to 55 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria every 3 cycles(each cycle is 14 days), ORR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response and partial response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 55 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria every 3 cycles(each cycle is 14 days), and DCR is the proportion of patients with reduction in tumor burden of a predefined amount, including complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from treatment beginning until the date of first documented progression, assessed up to 55 months</time_frame>
    <description>Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from treatment beginning until date of death from any cause, assessed up to 55 months</time_frame>
    <description>From date of treatment beginning until the date of death from any cause, through study completion, an average of 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Through study completion, an average of 4 weeks</time_frame>
    <description>Incidence of Treatment-related adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FIVC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>960mg po bid</description>
    <arm_group_label>FIVC group</arm_group_label>
    <other_name>PLX4032, RG7204</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500mg/m2 iv gtt (14 days per course)</description>
    <arm_group_label>FIVC group</arm_group_label>
    <other_name>ERBITUX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients have histologically or cytologically confirmed advanced or recurrent CRC;&#xD;
&#xD;
          -  Patients with BRAV V600E mutation/KRAS WT based on the NGS or ARMS-PCR detection of&#xD;
             tumor tissue;&#xD;
&#xD;
          -  Patients have measurable disease as defined by RECIST 1.1 as determined by&#xD;
             investigator;&#xD;
&#xD;
          -  Patient with a history of radiotherapy at least 3 months before on the day of&#xD;
             providing consent, but the measurable lesion should not be within the scope of&#xD;
             radiotherapy;&#xD;
&#xD;
          -  Patients without a history of receiving vemurafenib or cetuximab;&#xD;
&#xD;
          -  Patients with age of 18-75yr;&#xD;
&#xD;
          -  Patients with a performance status of 0,1or 2 on the Eastern Cooperative Oncology&#xD;
             Group.；&#xD;
&#xD;
          -  Patients with Life expectancy of more than 12 weeks;&#xD;
&#xD;
          -  Patients must have the ability to understand and sign the written informed consent&#xD;
             voluntarily;&#xD;
&#xD;
          -  Female of childbearing potential who are negative in a pregnancy test within 14 days&#xD;
             before enrollment. Both male and female patients should agree to use an adequate&#xD;
             method of contraception (total abstinence, an intrauterine device or hormone releasing&#xD;
             system, an contraceptive implant and an oral contraceptive) starting with the first&#xD;
             dose of study therapy through 120 days after the last dose of study therapy. Duration&#xD;
             will be determined when the subject is assigned to treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with KRAS/NRAS mutation;&#xD;
&#xD;
          -  Patients with major surgery or severe trauma within 4 weeks before the first&#xD;
             medication;&#xD;
&#xD;
          -  Patients with hypersensitivity to the components in the study protocol;；&#xD;
&#xD;
          -  Patients who are ready to give birth or are pregnant.。&#xD;
&#xD;
          -  Patients with brain metastases 。&#xD;
&#xD;
          -  Bone marrow, liver and kidney function did not meet the requirements of chemotherapy&#xD;
             as follows：&#xD;
&#xD;
               -  Neutrophil count&lt;1,500/mm3；&#xD;
&#xD;
               -  Platelet count &lt;80,000/mm3；&#xD;
&#xD;
               -  Total bilirubin &gt;1.5-times the upper limit of normal；&#xD;
&#xD;
               -  ALT/AST&gt;2.5-times the upper limit of normal for patients without liver&#xD;
                  metastases; (5.0-times the upper limit of normal for patients without liver&#xD;
                  metastases)&#xD;
&#xD;
               -  Creatinine &gt;1.5-times the upper limit of normal；&#xD;
&#xD;
          -  Patients with cancers other than advanced colorectal cancer within five years prior to&#xD;
             the start of treatment in this study. Cervical carcinoma in situ, cured basal cell&#xD;
             carcinoma and bladder epithelial tumor were excluded;；&#xD;
&#xD;
          -  Patients without legal capacity or limited civil capacity;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhan Wang, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan-Sheng Zang, Prof</last_name>
    <phone>+8613816584620</phone>
    <email>doctorzangys@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhan Wang, Prof.</last_name>
      <phone>+8613916229609</phone>
      <email>profoundamir@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Zhan Wang</investigator_full_name>
    <investigator_title>A single center clinical study of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.</investigator_title>
  </responsible_party>
  <keyword>FLOFIRI</keyword>
  <keyword>vemurafenib</keyword>
  <keyword>cetuximab</keyword>
  <keyword>BRAF V600E mutation</keyword>
  <keyword>Advanced Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

